Legend Biotech CEO shares sold for tax withholding

Legend Biotech Corp Chief Executive Officer Ying Huang reported the sale of 9,936 ordinary shares on March 25, 2026.

Rhea-AI Filing Summary

Legend Biotech Corp Chief Executive Officer Ying Huang reported the sale of 9,936 ordinary shares on March 25, 2026. The weighted average price was $8.77 per ordinary share. According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted share units. Following this transaction, Huang directly holds 247,438 ordinary shares.

Insider Trade Summary

Net Seller: 9,936 shares

Net Sell 1 txn

Insider Huang Ying

Role Chief Executive Officer

Sold 9,936 shs ($87K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	9,936	$8.77	$87K

Holdings After Transaction: Ordinary Shares — 247,438 shares (Direct)

Footnotes (3)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
2. F2. Represents shares sold to satisfy withholding tax obligations upon the vesting of restricted share units.
3. F3. The price reported in Column 4 is a weighted average price. The prices sold ranged from $17.26 to $17.82 per ADS (which is equivalent to $8.63 to $8.91 per ordinary share). The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Legend Biotech (LEGN) disclose for Ying Huang?

Legend Biotech disclosed that CEO Ying Huang had 9,936 ordinary shares sold on March 25, 2026. The filing notes these shares were sold to satisfy withholding tax obligations related to the vesting of restricted share units, rather than as a discretionary open-market sale.

How many Legend Biotech shares were involved in Ying Huang’s March 25, 2026 transaction?

The transaction involved 9,936 ordinary shares of Legend Biotech. These shares were sold in connection with tax withholding obligations arising from the vesting of restricted share units. After this sale, Huang’s directly held position stands at 247,438 ordinary shares of the company.

At what price were Ying Huang’s Legend Biotech shares sold in the Form 4?

The weighted average sale price reported was $8.77 per ordinary share. Footnotes explain actual prices ranged from $17.26 to $17.82 per ADS, which equates to $8.63 to $8.91 per ordinary share, because each ADS represents two ordinary shares.

Why were Ying Huang’s Legend Biotech shares sold according to the Form 4 footnotes?

The shares were sold to satisfy withholding tax obligations when restricted share units vested. This means the sale was tied to tax requirements on equity compensation, rather than a voluntary decision to reduce ownership in Legend Biotech’s ordinary shares.

How many Legend Biotech shares does CEO Ying Huang hold after the reported sale?

After the reported tax-related sale, Ying Huang directly holds 247,438 ordinary shares of Legend Biotech. This figure reflects his remaining direct ownership following the disposition of 9,936 shares associated with withholding tax obligations on vested restricted share units.

How are Legend Biotech ordinary shares related to its American Depositary Shares (ADSs)?

Each American Depositary Share of Legend Biotech represents two ordinary shares. The filing clarifies that reported ADS sale prices between $17.26 and $17.82 correspond to approximately $8.63 to $8.91 per ordinary share under this two-to-one ADS-to-ordinary-share ratio.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/27/2026 - 04:25 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huang Ying

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

2101 COTTONTAIL LANE

(Street)

SOMERSET NEW JERSEY 08873

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/25/2026		S(2)		9,936	D	$8.77(3)	247,438	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Represents shares sold to satisfy withholding tax obligations upon the vesting of restricted share units.

3. The price reported in Column 4 is a weighted average price. The prices sold ranged from $17.26 to $17.82 per ADS (which is equivalent to $8.63 to $8.91 per ordinary share). The reporting person will provide the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ James Pepin, Attorney-in-Fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)